Stoke Therapeutics Says FDA Willing To Accept Planned Phase 3 Cognition And Behavior Analysis For Zorevunersen In Dravet Syndrome
Share
Why It Matters
The FDA said it will accept Stoke's plan for testing a new Dravet medicine. This is a green light that moves the company closer to getting approval.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.